---
schema_version: "secwatch.filing_event.v1"
accession: "0001867096-23-000003"
form_type: "8-K"
ticker: "XERS"
cik: "0001867096"
company_name: "Xeris Biopharma Holdings, Inc."
filed_at: "2023-01-05T23:59:59+00:00"
generated_at: "2026-06-20T19:50:39.916290+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Xeris expects 2022 net product revenue at top of $105M-$110M guidance, cash >$120M

## Summary
- Expects 2022 net product revenue at top of guidance range of $105M-$110M.
- Year-end cash, cash equivalents, and short-term investments >$120M, above previous $110M-$120M range.
- FDA approved a generic version of Keveyis (dichlorphenamide); company believes it can defend the franchise.
- Does not anticipate need to raise equity to fund operations, citing commercial momentum and cash position.
- Q4 and FY22 financial results to be reported on or about March 8, 2023.

## SEC filing metadata
- accession: 0001867096-23-000003
- form_type: 8-K
- ticker: XERS
- cik: 0001867096
- company_name: Xeris Biopharma Holdings, Inc.
- filed_at: 2023-01-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/0001867096-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/xers-20230105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001867096-23-000003
- JSON: https://secwatch.observer/filing/0001867096-23-000003.json
- Plain text: https://secwatch.observer/filing/0001867096-23-000003.txt

## Key facts
- Earnings Releases
  Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).
  - Period: the year ended December 31, 2022
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2022 Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867096/000186709623000003/0001867096-23-000003-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.